Trial Profile

A 6-month prospective, randomized, double-blind, placebo-controlled clinical trial investigating the efficacy, safety, and tolerability of two different doses of buntanetap or placebo in patients with early Parkinson's disease

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 05 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Nov 2025 According to an Annovis Bio media release, The full biomarker data will be presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference in San Diego, December 1-4, 2025.
25 Mar 2025 According to an Annovis Bio media release, the company will take part in AD/PD™ 2025, taking place April 1-5 in Vienna, and At this meeting the company will present comprehensive data from this Phase 3 PD study.
03 Mar 2025 According to ClinicalTrials.gov by the U.S. National Institutes of Health, the primary safety endpoint has been removed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com